Korro Bio, Inc. (KRRO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Korro Bio, Inc. on August 28, 2024, covering events that occurred on August 26, 2024. The company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol KRRO.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and specific compensatory arrangements.
Material Changes
- Director Resignation: David L. Lucchino resigned from the Board of Directors effective immediately on August 26, 2024. The resignation was not due to any disagreement with management or the Board regarding operations, policies, or practices.
- Board Composition Adjustment: The Board reduced the number of directors from seven to six to eliminate the vacancy in Class I, then increased the number back to seven to create a vacancy in Class III.
- New Director Appointment: Katharine Knobil, M.D., was appointed to fill the Class III vacancy effective immediately. She will serve until the 2025 annual meeting of stockholders and was also appointed to the Compensation Committee.
Compensatory Arrangements and Outlook
As part of the transition, the company entered into a consulting agreement with the departing director, Mr. Lucchino, and established standard compensation for the new director, Dr. Knobil.
- Mr. Lucchino Consulting Agreement:
- Term: Until the earlier of October 1, 2027, termination by either party, or death.
- Cash Compensation: $9,000 per quarter through the 2026 annual meeting; $2,000 per quarter through the 2027 annual meeting.
- Equity Grant: An option grant valued at $150,000 (capped at 8,000 shares) to be granted at the 2025 annual meeting, vesting fully at the 2026 annual meeting.
- Expenses: Reimbursement of up to $10,000 for negotiation expenses.
- Dr. Knobil Compensation: She will receive compensation as a non-employee director in accordance with the company's policy described in a prior Form 8-K filed on November 6, 2023. A standard director indemnification agreement was also executed.
Investor Verification Checklist
- Verify the specific terms of the non-employee director compensation policy referenced in the November 6, 2023 Form 8-K to determine Dr. Knobil's exact compensation.
- Review the full text of the consulting agreement with Mr. Lucchino (Exhibit 10.1) to understand termination clauses and "Cause" definitions.
- Confirm the vesting schedule and exercise price of the option grant to be issued to Mr. Lucchino at the 2025 annual meeting.
- Monitor future filings for the formal election of Dr. Knobil at the 2025 annual meeting of stockholders.